标题
The History of Early Breast Cancer Treatment
作者
关键词
-
出版物
Genes
Volume 13, Issue 6, Pages 960
出版商
MDPI AG
发表日期
2022-05-27
DOI
10.3390/genes13060960
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
- (2022) Rosie Bradley et al. LANCET ONCOLOGY
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
- (2021) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
- (2020) Junjie Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial
- (2020) Philip M Poortmans et al. LANCET ONCOLOGY
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
- (2019) Johan Staaf et al. NATURE MEDICINE
- Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
- (2019) Olivia Pagani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
- (2018) Noah Kornblum et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients
- (2017) Mirelle Lagendijk et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2017) Armando E. Giuliano et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
- (2017) Charlotte E Coles et al. LANCET
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer
- (2016) Lise Bech Jellesmark Thorsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial
- (2015) Lorenzo Livi et al. EUROPEAN JOURNAL OF CANCER
- Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
- (2015) Philip M. Poortmans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- A Systematic Review of Complications of Implant-based Breast Reconstruction with Prereconstruction and Postreconstruction Radiotherapy
- (2013) Adeyiza O. Momoh et al. ANNALS OF SURGICAL ONCOLOGY
- The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients
- (2013) Judith Hurley et al. BREAST CANCER RESEARCH AND TREATMENT
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
- (2013) Judy C. Boughey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial
- (2013) Umberto Veronesi et al. LANCET ONCOLOGY
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
- (2013) Thorsten Kuehn et al. LANCET ONCOLOGY
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- (2012) N. Mavaddat et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast Cancer
- (2012) Grace L. Smith et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial
- (2012) Saskia Litière et al. LANCET ONCOLOGY
- Finding CDK: Linking yeast with humans
- (2012) Paul Nurse NATURE CELL BIOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
- (2006) V Craig Jordan BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now